Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials.
Sullivan JC, De Meyer S, Bartels DJ, Dierynck I, Zhang EZ, Spanks J, Tigges AM, Ghys A, Dorrian J, Adda N, Martin EC, Beumont M, Jacobson IM, Sherman KE, Zeuzem S, Picchio G, Kieffer TL.
Sullivan JC, et al. Among authors: ghys a.
Clin Infect Dis. 2013 Jul;57(2):221-9. doi: 10.1093/cid/cit226. Epub 2013 Apr 10.
Clin Infect Dis. 2013.
PMID: 23575197
Clinical Trial.